Samsung BiologicsLtd Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
John Chongbo Rim
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 3.4yrs |
| CEO ownership | n/a |
| Management average tenure | 1.8yrs |
| Board average tenure | 4.2yrs |
Recent management updates
Recent updates
What Samsung Biologics Co.,Ltd.'s (KRX:207940) P/E Is Not Telling You
Apr 14
With EPS Growth And More, Samsung BiologicsLtd (KRX:207940) Is Interesting
Mar 01These 4 Measures Indicate That Samsung BiologicsLtd (KRX:207940) Is Using Debt Reasonably Well
Jan 18
What Kind Of Shareholders Own Samsung Biologics Co.,Ltd. (KRX:207940)?
Dec 28How Much Is Samsung Biologics Co.,Ltd. (KRX:207940) CEO Getting Paid?
Dec 08Did You Miss Samsung BiologicsLtd's (KRX:207940) Impressive 112% Share Price Gain?
Nov 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | ₩858b |
| Sep 30 2023 | n/a | n/a | ₩937b |
| Jun 30 2023 | n/a | n/a | ₩826b |
| Mar 31 2023 | n/a | n/a | ₩793b |
| Dec 31 2022 | n/a | n/a | ₩798b |
| Sep 30 2022 | n/a | n/a | ₩507b |
| Jun 30 2022 | n/a | n/a | ₩510b |
| Mar 31 2022 | n/a | n/a | ₩480b |
| Dec 31 2021 | ₩3b | ₩598m | ₩394b |
| Sep 30 2021 | n/a | n/a | ₩410b |
| Jun 30 2021 | n/a | n/a | ₩335b |
| Mar 31 2021 | n/a | n/a | ₩265b |
| Dec 31 2020 | ₩995m | ₩421m | ₩241b |
| Sep 30 2020 | n/a | n/a | ₩355b |
| Jun 30 2020 | n/a | n/a | ₩343b |
| Mar 31 2020 | n/a | n/a | ₩278b |
| Dec 31 2019 | ₩1b | ₩497m | ₩203b |
Compensation vs Market: Insufficient data to establish whether John Chongbo's total compensation is reasonable compared to companies of similar size in the KR market.
Compensation vs Earnings: John Chongbo's compensation has increased by more than 20% in the past year.
CEO
John Chongbo Rim (62 yo)
3.4yrs
Tenure
₩3,125,000,000
Compensation
Mr. John Chongbo Rim serves as Chairman of Samsung Biologics Co.,Ltd. since March 17, 2023. He has been the CEO & President of Samsung Biologics Co.,Ltd.since December 16, 2020. Mr. Rim has been Director...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Chairman of Board | 3.4yrs | ₩3.13b | no data | |
| CFO, Executive VP | 9.4yrs | ₩666.00m | 0.0065% ₩ 3.6b | |
| Executive Director | no data | ₩2.19b | no data | |
| Executive VP and Head of Bio R&D Centre & CSO | 1.4yrs | no data | no data | |
| Vice President & Head of Legal Compliance Team | no data | no data | no data | |
| Executive VP | 1.3yrs | ₩569.00m | no data | |
| Vice President | 2.2yrs | no data | no data | |
| Executive VP & Head of CDO Development Center | 1.3yrs | no data | no data | |
| VP & Head of Business Consulting Team | no data | no data | no data | |
| Executive VP & Head of EPCV Center | no data | no data | no data | |
| Executive VP & Head of Manufacturing Center | no data | no data | no data | |
| VP & Head of Business Strategy | no data | no data | no data |
1.8yrs
Average Tenure
56yo
Average Age
Experienced Management: A207940's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Chairman of Board | 4.2yrs | ₩3.13b | no data | |
| CFO, Executive VP | 5.2yrs | ₩666.00m | 0.0065% ₩ 3.6b | |
| Executive Director | 4.2yrs | ₩2.19b | no data | |
| Independent Outside Director | 4.2yrs | no data | no data | |
| Independent Director | no data | no data | no data | |
| Independent Director | 2.3yrs | no data | no data | |
| Independent Director | 5.2yrs | no data | no data | |
| Independent Director | 1.2yrs | no data | no data |
4.2yrs
Average Tenure
64yo
Average Age
Experienced Board: A207940's board of directors are considered experienced (4.2 years average tenure).